Welcome to our dedicated page for Im Cannabis SEC filings (Ticker: IMCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IM Cannabis Corp. (IMCC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. IM Cannabis files reports with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F and multiple current reports on Form 6-K.
Through these filings, investors can review financial statements and MD&A for IM Cannabis’ operations in Israel and Germany. Form 6-K submissions include unaudited interim condensed consolidated financial statements and management’s discussion and analysis for periods such as the three and nine months ended September 30, 2025. These documents discuss revenue, gross margin, operating expenses, non-IFRS measures like Adjusted EBITDA, and notes regarding the company’s ability to continue as a going concern.
Filings also cover governance and leadership changes, such as the appointment of a new Chief Financial Officer, the planned departure of the previous CFO, and board and committee changes. Related Form 6-K reports often attach the underlying press releases and describe whether any related party transactions are present or need disclosure under Form 20-F requirements.
Another important category is capital markets and securities information. IM Cannabis has filed Form 6-K reports detailing amendments to common share purchase warrants, including changes to exercise prices and expiration dates, as well as the filing of a resale registration statement on Form F-3. Early warning and related party disclosures are also summarized in these materials.
Stock Titan’s platform surfaces these IMCC filings as they are furnished to EDGAR and applies AI-powered summaries to help explain the contents of lengthy documents, such as MD&A sections and financial statement notes. Users can quickly locate quarterly information, board and management updates, and transaction-related disclosures, while also drilling down into the full text of Form 6-K and Form 20-F filings when deeper analysis is required.
IM Cannabis Corp. (IMCC) filed a Form 6-K announcing a new debt financing and a board change. On 6 July 2025 the company signed a Loan Agreement with L.I.A. Pure Capital Ltd. for up to US$2 million. The company has already received the first tranche of US$1 million; a second tranche of US$1 million may be drawn within 60 days, contingent on unspecified conditions.
The agreement grants the lender a right to recommend one director to the board. Pursuant to this right, Mr. Oz Adler, CPA, was appointed to IMCC’s board effective 6 July 2025. Adler is currently CEO and CFO of SciSparc Ltd. and sits on the boards of several Nasdaq-listed companies, bringing managerial, accounting and capital-markets experience.
The Loan Agreement (Exhibit 10.1) and a related press release dated 9 July 2025 (Exhibit 99.1) are furnished with the filing. Except for two specified paragraphs of the press release, the entire 6-K is incorporated by reference into IMCC’s Form F-3 registration statement (File No. 333-288346).
Key takeaways for investors:
- Immediate liquidity boost of US$1 million with potential for an additional US$1 million.
- New debt introduces repayment obligations not yet disclosed in the filing.
- Lender’s nomination right and Adler’s appointment modestly alter board composition.
IM Cannabis Corp. (Nasdaq: IMCC) has filed a Form F-3 shelf registration allowing it to issue up to $50 million in securities, including common shares, warrants or units combining the two. The filing provides the company with flexibility to raise capital "from time to time" through direct sales, agents, underwriters or dealers, as detailed in the forthcoming prospectus supplements.
The company’s non-affiliate market capitalization was approximately $15.9 million on 26 June 2025, based on 4,044,812 outstanding shares at a May 30 closing price of $6.20. The most recent Nasdaq trading price (25 June 2025) was $2.77 per share. IM Cannabis qualifies as both an emerging growth company (EGC) under the JOBS Act and a foreign private issuer, permitting streamlined disclosure obligations.
The registration statement invokes Rule 415, confirming that the securities may be issued on a continuous or delayed basis. The company has not sold securities under General Instruction I.B.5 in the previous 12 months. Risk disclosures, pricing, fees and use-of-proceeds will be provided in each prospectus supplement, and any related free-writing prospectus may update or modify the base document.
Proceeds are expected to support corporate purposes yet to be specified; investors are cautioned to review the "Risk Factors" section (page 4) once available. No securities may be sold until the SEC declares the shelf effective, and offers are limited to jurisdictions where lawful.